Nurix Therapeutics officer plans $130K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Nurix Therapeutics, Inc. officer Christine Ring reported a planned sale of 8,148 common shares, with an aggregate market value of $130,123.56 and an approximate sale date of March 2, 2026. Morgan Stanley Smith Barney LLC is listed as broker. The shares were acquired upon vesting of restricted stock units between May 2, 2022 and January 30, 2025. The notice gives November 10, 2025 as the Rule 10b5-1 plan adoption or instruction date. It also lists four prior 10b5-1 sales: 8,148 shares for gross proceeds of $135,757.90 and 6,113 shares for $101,860.92 on February 9, 2026; 3,760 shares for $69,273.11 on January 20, 2026; and 3,760 shares for $67,314.15 on December 18, 2025.
Key Figures
Key Terms
Restricted Stock Units financial
Rule 10b5-1 regulatory
Aggregate Market Value financial
Gross Proceeds financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What earlier NRIX stock sales did Christine Ring report?
AI-generated analysis. How Rhea-AI works. Not financial advice.